Beacon Angels Meetings '24-'25

Monthly breakfast meeting where Beacon Angels members and guests entertain startup funding proposals and review portfolio company needs

We shall entertain new funding proposals as follows:  

8:30 - 9:00 AM, Alpha Cure Therapeutics, developing precision safe radioligand therapy via small molecule next-generation BNCT, initially focused on Triple Negative Breast Cancer ; and

9:15 - 9:45 AM, LexaGene Life Sciences, creating a device used for microbial contamination detection in drug manufacturing to reduce the time for detection.

10:00 - 10:30 AM, Joined Bio, creating a direct-to-patient marketplace that initially helps researchers get biospecimens from patients, and ultimately enables patients to manage access to their data, participate in clinical trials, etc.

Members will report on current funding rounds, by Series number.

S96C - NF2 Therapeutics, Inc. ($67K)

S134 - eCare Vault ($15K pro rata)

S136 - NIRA (new bridge round; $43K pro rata)

S137 - Lenoss Medical (2025 bridge round)

S139 - Neosoma ($800k bridge debt to Series A; $150K invested thus far)

S140 - AI Lean offering fully automated lien compliance to storage companies;

S141 - GelMEDIX, raising up to $4 MM to complete critical pharmacology and toxicology studies before Series A.

Members will report on the following companies now in due diligence: 

IRIS Therapeutic Devices developing a device to treat and reverse the effects of Parkinson's disease.